3 Cannabis Stocks We Were Right On From The Beginning

During the last decade, the legal cannabis industry has made incredible advancements as countries across the globe have legalized or decriminalized the plant. In the US, several of the largest states have legalized cannabis while it remains illegal at the federal level and this has made the investing process more complex.

The reason why the cannabis investing process is complex is because major financial institutions and broker-dealers in the US cannot provide any information to clients on the sector. Since cannabis is considered to be illegal at the federal level, Wall Street financial firms are not allowed to cover US cannabis companies, and this has made it more difficult for the market to be aware of the legitimate opportunities in the sector.

In 2014, we started to cover the cannabis sector and have watched how the industry has advanced in such a short period of time. Back when we started to cover the sector, there were only a few companies that we would consider to be legitimate. Over the last few years, we have put a major emphasis on legitimate companies and want to highlight 3 companies that we were ahead of the street on.

GW Pharmaceuticals: An Execution Story to be Aware of

GW Pharmaceuticals PLC (GWPH) is the first company that we want to highlight and is an opportunity that we continue to be excited about. The company has a deep pipeline of pharmaceutical products that are in advanced stages of Food and Drug Administration (FDA) clinical trials.

From 2014 to early 2016, we considered GW to be one of the most underappreciated opportunities on the Nasdaq and highlighted the business on a number of occasions. In March 2016, GW skyrocketed after it issued positive data for a Phase 3 clinical trial on Dravet’s Syndrome. Following the positive report, GW jumped almost 100%, and we were glad to be ahead of the market on the opportunity.

When compared to its peers, GW has the most coverage from Wall Street broker-dealers, and we are favorable on this. Currently, the company is trading below its average price target, and we will be keeping an eye on how the management team is able to bring additional cannabis derived treatments to market.

1 2 3
View single page >> |

Disclosure: This report was authored by and is property of Technical420. All information and data relied upon in drafting this report is publicly available. The author believes and considers its ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.